MASHdoc_SA said:ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase…
Genuinely useful, thank you. I had the facts and not the framework.
Clinical perspective, offered as context rather than as advice. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.
Dr.GastroMayo said:Liver imaging follow-up for liver and MASH: FibroScan at baseline showed CAP score 326 dB/m (moderate steatosis) and stiffness 10.8 kPa (possible…
This is where I part company with the consensus forming above. The counter-case has not been addressed. Somebody upthread described the situation that does not fit, and the thread moved on rather than engaging with it, which is the failure mode this board is supposed to avoid.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsThe figures, for anyone assembling their own picture. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.
Moderator note: the sourcing question belongs in the vendor section and has been split out. Thread quality here is what the rules are for. Keep it up.